SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).
CKD5D
COVID-19
Hemodialysis
Kidney
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
20
11
2021
accepted:
03
04
2022
pubmed:
30
4
2022
medline:
31
1
2023
entrez:
29
4
2022
Statut:
ppublish
Résumé
Patients suffering from chronic kidney disease (CKD) are in general at high risk for severe coronavirus disease (COVID-19) but dialysis-dependency (CKD5D) is poorly understood. We aimed to describe CKD5D patients in the different intervals of the pandemic and to evaluate pre-existing dialysis dependency as a potential risk factor for mortality. In this multicentre cohort study, data from German study sites of the Lean European Open Survey on SARS-CoV-2-infected patients (LEOSS) were used. We multiply imputed missing data, performed subsequent analyses in each of the imputed data sets and pooled the results. Cases (CKD5D) and controls (CKD not requiring dialysis) were matched 1:1 by propensity-scoring. Effects on fatal outcome were calculated by multivariable logistic regression. The cohort consisted of 207 patients suffering from CKD5D and 964 potential controls. Multivariable regression of the whole cohort identified age (> 85 years adjusted odds ratio (aOR) 7.34, 95% CI 2.45-21.99), chronic heart failure (aOR 1.67, 95% CI 1.25-2.23), coronary artery disease (aOR 1.41, 95% CI 1.05-1.89) and active oncological disease (aOR 1.73, 95% CI 1.07-2.80) as risk factors for fatal outcome. Dialysis-dependency was not associated with a fatal outcome-neither in this analysis (aOR 1.08, 95% CI 0.75-1.54) nor in the conditional multivariable regression after matching (aOR 1.34, 95% CI 0.70-2.59). In the present multicentre German cohort, dialysis dependency is not linked to fatal outcome in SARS-CoV-2-infected CKD patients. However, the mortality rate of 26% demonstrates that CKD patients are an extreme vulnerable population, irrespective of pre-existing dialysis-dependency.
Identifiants
pubmed: 35486356
doi: 10.1007/s15010-022-01826-7
pii: 10.1007/s15010-022-01826-7
pmc: PMC9052729
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-81Investigateurs
Julia Lanznaster
(J)
Bjoern-Erik Jensen
(BE)
Martin Hower
(M)
Bernd Hohenstein
(B)
Timm Westhoff
(T)
Maria Vehreschild
(M)
Christoph Spinner
(C)
Maria Madeleine Ruethrich
(MM)
Lukas Tometten
(L)
Stefan Borgmann
(S)
Norma Jung
(N)
Bernd Hertenstein
(B)
Christian Degenhardt
(C)
Ingo Voigt
(I)
Frank Hanses
(F)
Kai Wille
(K)
Juergen Vom Dahl
(JV)
Katja Rothfuss
(K)
Kerstin Hellwig
(K)
Jan Rupp
(J)
Nora Isberner
(N)
Lukas Eberwein
(L)
Jacob Nattermann
(J)
Richard Strauss
(R)
Sebastian Dolff
(S)
Siri Göpel
(S)
Jörg Janne Vehreschild
(JJ)
Susana M Nunes de Miranda
(SMN)
Carolin E M Jakob
(CEM)
Melanie Stecher
(M)
Lisa Pilgram
(L)
Nick Schulze
(N)
Sandra Fuhrmann
(S)
Max Schons
(M)
Annika Claßen
(A)
Bernd Franke
(B)
Fabian Prasser
(F)
Informations de copyright
© 2022. The Author(s).
Références
Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ .
Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020;46:1114–6.
doi: 10.1007/s00134-020-06026-1
Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S, Covid, Ace2 in Cardiovascular L, Kidney Working G. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31:1380–3.
doi: 10.1681/ASN.2020040419
Braun F, Lutgehetmann M, Pfefferle S, Wong MN, Carsten A, Lindenmeyer MT, Norz D, Heinrich F, Meissner K, Wichmann D, et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet. 2020;396:597–8.
doi: 10.1016/S0140-6736(20)31759-1
Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77:190–203.
doi: 10.1053/j.ajkd.2020.09.003
Council E-E, Group EW. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36:87–94.
doi: 10.1093/ndt/gfaa314
Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, Jhaveri KD, Fishbane S, Northwell C-RC, the Northwell Nephrology C-RC. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98:1530–9.
doi: 10.1016/j.kint.2020.07.030
Pilgram L, Eberwein L, Wille K, Koehler FC, Stecher M, Rieg S, Kielstein JT, Jakob CEM, Ruthrich M, Burst V et al. Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. Infection. 2021.
Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sanchez-Alvarez JE, Garneata L, Collart F, Hemmelder MH, Ambuhl P, Kerschbaum J, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98:1540–8.
doi: 10.1016/j.kint.2020.09.006
Hoxha E, Suling A, Turner JE, Haubitz M, Floege J, Huber TB, Galle JC. COVID-19 prevalence and mortality in chronic dialysis patients. Dtsch Arztebl Int. 2021;118:195–6.
Veklury—remdesivir. https://www.ema.europa.eu/en/medicines/human/EPAR/veklury .
Schieber TJ, Bennett N, Aragon L, Ploetz J, Boyd S. Real-world risk evaluation of remdesivir in patients with an estimated glomerular filtration rate of less than 30 mL/min. Am J Health Syst Pharm. 2021.
Pilgram L, Schons M, Jakob CEM, Classen AY, Franke B, Tscharntke L, Schulze N, Fuhrmann S, Sauer G, de Miranda SMN, et al. The COVID-19 pandemic as an opportunity and challenge for registries in health services research: lessons learned from the lean European open survey on SARS-CoV-2 infected patients (LEOSS). Gesundheitswesen. 2021;83:S45–53.
doi: 10.1055/a-1655-8705
group TLs. LEOSS metadata on medical data models (mdm) portal. In.; 2021.
Jakob CEM, Kohlmayer F, Meurers T, Vehreschild JJ, Prasser F. Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. Sci Data. 2020;7:435.
doi: 10.1038/s41597-020-00773-y
Nextstrain: CoVariants. https://covariants.org/per-variant?country=Germany .
Team RC. R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing; 2021.
Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, Friedrichs A, Tometten L, Hanses F, Jung N, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2021;49:63–73.
doi: 10.1007/s15010-020-01499-0
The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–40.
doi: 10.1056/NEJMoa2022926
Kluge S, Janssens U, et al. S2k Leitlinie—Empfehlungen zur stationären Therapie von Patienten mit COVID-19. In. AWMF online. 2021.
Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704.
doi: 10.1056/NEJMoa2021436
Rochwerg B, Agarwal A, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo Y-S, Macdonald H, Zeng L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–42.
doi: 10.1001/jama.2020.2648
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
doi: 10.1038/s41586-020-2521-4
Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Ren Replace Ther. 2021;7:59.
doi: 10.1186/s41100-021-00378-0
Consortium C-CC, Group LS. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J. 2021.
Werfel S, Jakob CEM, Borgmann S, Schneider J, Spinner C, Schons M, Hower M, Wille K, Haselberger M, Heuzeroth H, et al. Development and validation of a simplified risk score for the prediction of critical COVID-19 illness in newly diagnosed patients. J Med Virol. 2021;93:6703–13.
doi: 10.1002/jmv.27252
Jakob CEM, Mahajan UM, Oswald M, Stecher M, Schons M, Mayerle J, Rieg S, Pletz M, Merle U, Wille K, et al. Prediction of COVID-19 deterioration in high-risk patients at diagnosis: an early warning score for advanced COVID-19 developed by machine learning. Infection. 2021;50:359.
doi: 10.1007/s15010-021-01656-z
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:382–386.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
doi: 10.1136/bmj.m1091
Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, Cooper R, House AA, McFarlane P, Blake PG. COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ. 2021;193:E278–84.
doi: 10.1503/cmaj.202601
Couchoud C, Bayer F, Ayav C, Bechade C, Brunet P, Chantrel F, Frimat L, Galland R, Hourmant M, Laurain E, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int. 2020;98:1519–29.
doi: 10.1016/j.kint.2020.07.042
Zou R, Chen F, Chen D, Xu CL, Xiong F. Clinical characteristics and outcome of hemodialysis patients with COVID-19: a large cohort study in a single Chinese center. Ren Fail. 2020;42:950–7.
doi: 10.1080/0886022X.2020.1816179
Savino M, Santhakumaran S, Evans KM, Steenkamp R, Benoy-Deeney F, Medcalf JF, Nitsch D. Outcomes of patients with COVID-19 on kidney replacement therapy: a comparison among modalities in England. Clin Kidney J. 2021;14:2573–81.
doi: 10.1093/ckj/sfab160
Carriazo S, Mas-Fontao S, Seghers C, Cano J, Goma E, Avello A, Ortiz A, Gonzalez-Parra E. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study. Clin Kidney J. 2022;15:432–41.
doi: 10.1093/ckj/sfab248
Jahn M, Korth J, Dorsch O, Anastasiou OE, Krawczyk A, Brochhagen L, van de Sand L, Sorge-Hadicke B, Tyczynski B, Witzke O et al. Decline of humoral responses 6 months after vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines (Basel). 2022; 10.